Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11524980 | 0.96 | TSHR (0.50) | TSHRTHRBLMNAANPEPSLC22A1 | |
| SCHEMBL88650 | 0.96 | TSHR (0.50) | TSHRTHRBLMNAANPEPSLC22A1 | |
| SCHEMBL332105 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL487870 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL11331724 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL2495893 | 0.93 | TSHR (0.47) | TSHRTHRBLMNAANPEPSLC22A1 | |
| SCHEMBL488468 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL8845927 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL556924 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL29385729 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810967-B1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INT INC (TW) | 2014-07-30 | — | — | EP | claimed |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | claimed |
| US-7309803-B2 | Clean, High-yield preparation of S,S and R,S amino acid isosteres | AEROJET FINE CHEMICALS LLC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1810967-A1 | Processes and intermediates for the preparations of prostaglandins | Chirogate International Inc. (TW) | 2007-07-25 | — | — | EP | claimed |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2007-07-19 | — | — | US | claimed |
| WO-1995027715-A2 | METHOD OF MANUFACTURE OF (-)GALANTHAMINE IN HIGH YIELD AND PURITY SUBSTANTIALLY FREE OF EPIGALANTHAMINE | CIBA-GEIGY CORPORATION (US) | 1995-10-19 | — | — | WO | claimed |
| US-5428159-A | Resolution of racemic mixture; reduction | CIBA-GEIGY CORPORATION (US) | 1995-06-27 | — | — | US | claimed |
| US-12497375-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | CHIROGATE INTERNATIONAL INC. (TW) | 2025-12-16 | — | — | US | disclosed |
| US-12497374-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | CHIROGATE INTERNATIONAL INC. (TW) | 2025-12-16 | — | — | US | disclosed |
| US-20250304519-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | CHIROGATE INTERNATIONAL INC. (TW) | 2025-10-02 | — | — | US | disclosed |
| US-12428361-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | CHIROGATE INTERNATIONAL INC. (TW) | 2025-09-30 | — | — | US | disclosed |
| EP-4273131-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | CHIROGATE INT INC (TW) | 2025-07-02 | — | — | EP | disclosed |
| US-12221411-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | CHIROGATE INTERNATIONAL INC. (TW) | 2025-02-11 | — | — | US | disclosed |
| EP-0527962-A4 | METHOD, COMPOSITIONS, AND COMPOUNDS FOR MODULATING BRAIN EXCITABILITY | — | 1993-10-20 | — | — | EP | disclosed |
| US-5208227-A | Stress relieving and anxiety modulators | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0527962-A1 | METHOD, COMPOSITIONS, AND COMPOUNDS FOR MODULATING BRAIN EXCITABILITY | GEE, Kelvin W. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5120723-A | Alleviate stress, anxiety, seizures | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-06-09 | — | — | US | disclosed |
| WO-1991016897-A1 | METHOD, COMPOSITIONS, AND COMPOUNDS FOR MODULATING BRAIN EXCITABILITY | WELLMAN GEE KELVIN (US) | 1991-11-14 | — | — | WO | disclosed |
| US-4578482-A | Process for preparing prostacyclins | TEIJIN LIMITED (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0113577-A1 | Process for preparing prostacyclins | TEIJIN LIMITED (JP) | 1984-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428361-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | PTGIS, PTGIR, PTGES | TSHR 4673/4885THRB 4728/4885LMNA 500/4885 |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | TSHR 2650/4885THRB 3669/4885LMNA 1678/4885 |
| US-12221411-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | PTGIS, PTGIR, PTGES | TSHR 4673/4885THRB 4728/4885LMNA 500/4885 |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | TSHR 2650/4885THRB 3669/4885LMNA 1678/4885 |
| US-12497374-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | PTGIS, PTGER1, PTGIR | TSHR 2552/4885THRB 3405/4885LMNA 346/4885 |
| US-20250304519-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | PTGIS, PTGIR, PTGES | TSHR 4673/4885THRB 4728/4885LMNA 500/4885 |
| US-12497375-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | PTGIS, PTGIR, PTGES | TSHR 3431/4885THRB 4431/4885LMNA 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.